FDA denies Bharat Bio’s US partner emergency approval for Covaxin vaccine en

0
3

Press Trust of India  | 
Hyderabad 
Last Updated at June 11, 2021 13:17 IST

In setback that could potentially delay the launch of Bharat Biotech’s COVID-19 vaccine Covaxin in USA, the Food and Drug Administration there has « recommended » Ocugen Inc, the US partner of the Indian vaccine maker, to go for Biologics Licence Application (BLA) route with additional data, nixing hopes of Emergency Use Authorisation.

Ocugen in a statement on Thursday announced that as recommended by the FDA, it will pursue submission of a biologics licence application (BLA) for Covaxin.document.write(« « );googletag.cmd.push(function(){googletag.defineOutOfPageSlot(‘/6516239/outofpage_1x1_desktop’,’div-gpt-ad-1490771277198-0′).addService(googletag.pubads());googletag.pubads().enableSyncRendering();googletag.enableServices();});

« The company will no longer pursue an Emergency Use Authorization (EUA) for Covaxin. The FDA provided feedback to Ocugen regarding the Master File. The company had previously submitted and recommended that Ocugen pursue a BLA submission instead of an EUA application for its vaccine candidate and requested additional information and data, » Ocugen said.

Ocugen is in discussions with the FDA to understand the additional information required to support a BLA submission.

The company anticipates that data from an additional clinical trial will be required to support the submission.

« Although we were close to finalising our EUA application for submission, we received a recommendation from the FDA to pursue a BLA path. While this will extend our timelines, we are committed to bringing Covaxin to the US, » Dr. Shankar Musunuri, Chairman of the Board, Chief Executive Officer and co-founder of Ocugen said.

« This differentiated vaccine is a critical tool to include in our national arsenal given its potential to address the SARS-CoV-2 variants, including the delta variant, and given the unknowns about what will be needed to protect US population in the long term, » he added.

Reacting to the FDA »s « recommendation », Bharat Biotech said with good herd immunity and significant percentage of the population vaccinated, the pandemic is reducing in the United States, the US regulator had earlier communicated that no new EUAs will be approved for COVID-19 vaccines.

« All applications have to follow the biological license application process, which is the standard process for vaccines. Data from an additional clinical trial will be required to support the marketing application submission for Covaxin, » the vaccine maker said.

No vaccine manufactured or developed from India has ever received EUA or full licensure from USFDA.

When approved, it will be a « great leap forward » for vaccines » innovation and manufacturing from India, Bharat Biotech added.

Ocugen recently announced that it secured exclusive rights to commercialise Covaxin in Canada and has initiated discussions with Health Canada for regulatory approval.

The company will pursue expedited authorisation for the vaccine under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 in Canada.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is happy to inform you of the launch of « Business Standard Premium Services »

As a premium subscriber you get an across device unfettered access to a range of services which include:

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.
Enjoy Reading!
Team Business Standard

Related title:
FDA denies Bharat Bio's US partner emergency approval for Covaxin vaccine
US FDA Denies Covaxin Emergency Use Approval
Why was Bharat Biotech's Covaxin not approved in US? Here's what we know so far
Coronavirus: US drug regulator rejects emergency use approval for Bharat Biotech's Covaxin
FDA rejects EUA for Covaxin, 'suggests' Biologics Licence Application route for approval in US
Coronavirus News LIVE: US FDA delays EUA of Covaxin in country, seeks more data through BLA route
Covaxin's US approval delayed as FDA asks for more data
Here's Why FDA Rejected Covaxin's Emergency Use in America
US FDA rejects emergency use approval for Bharat Biotech's Covaxin
US FDA rejects emergency authorisation for Covaxin, 'recommends' to take full approval route

en

Keywords:

Vaccine,Food and Drug Administration,Emergency Use Authorization,Vaccine, Food and Drug Administration, Emergency Use Authorization,,

QU’EN PENSEZ-VOUS?

[comment]

PUB

Laisser un commentaire, votre avis compte!

[gs-fb-comments] [comment-form]